Live
FierceBiotechAltai Capital angles for OraSure board seats and a saleFierceBiotechXaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'Cytiva (Google News)Class action accuses Danaher of turning DEI into hiring quotas - hcamag.comEndpoints NewsCMS innovation center to expand team focused on drug pricesEndpoints NewsAldeyra dry eye drug gets third rejection from FDA, triggering stock slide10x Genomics Blog10x Genomics (NASDAQ:TXG) Stock Price Up 6.9% - Time to Buy? - MarketBeatEndpoints NewsDrugmakers consider licensing deal tweaks to soften MFN impactThermo FisherHow Niton XRF Technology is Transforming Precious Metals Analysis - AZoMEndpoints NewsKaren Weintraub and Kevin Miller to join Endpoints News as editorsEndpoints NewsThe latest in Epic's fight over patient health dataFierceBiotechAlcon, Lensar drop $356M acquisition deal after black eye from FTCFierceBiotechFDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings
Endpoints News Mar 17, 2026

Karen Weintraub and Kevin Miller to join Endpoints News as editors

Karen Weintraub and Kevin Miller to join Endpoints News as editors

Original
Body unavailable. Use the original source.

Directory

59 All